{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T11:18:48Z","timestamp":1773400728747,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:00:00Z","timestamp":1771977600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Chem Res"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s00044-026-03532-7","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T18:11:47Z","timestamp":1772043107000},"page":"649-663","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Synthesis and structure-activity relationship evaluation of hypoglycemic activity of novel borneol and isoborneol containing (hydroxyphenyl)propanoic acids as FFAR1 agonists"],"prefix":"10.1007","volume":"35","author":[{"given":"Sergey O.","family":"Kuranov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikhail V.","family":"Larin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina D.","family":"Levchenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yulia V.","family":"Meshkova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariya K.","family":"Marenina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olga A.","family":"Luzina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikhail V.","family":"Khvostov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatiana G.","family":"Tolstikova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nariman F.","family":"Salakhutdibov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,25]]},"reference":[{"issue":"1","key":"3532_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/ndt\/gfaf177","volume":"41","author":"BB Duncan","year":"2025","unstructured":"Duncan BB, Magliano DJ, Boyko EJ. IDF Diabetes Atlas 11th edition 2025: global prevalence and projections for 2050. Nephrol Dial Transplant. 2025;41(1):7\u20139. https:\/\/doi.org\/10.1093\/ndt\/gfaf177.","journal-title":"Nephrol Dial Transplant"},{"issue":"10","key":"3532_CR2","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1016\/S2213-8587(23)00223-1","volume":"11","author":"Emerging Risk Factors Collaboration.","year":"2023","unstructured":"Emerging Risk Factors Collaboration. Life expectancy associated with different ages at diagnosis of type 2 diabetes in high-income countries: 23 million person-years of observation. Lancet Diabetes Endocrinol. 2023;11(10):731\u201342. https:\/\/doi.org\/10.1016\/S2213-8587(23)00223-1.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"3532_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114252","volume":"159","author":"Q Hu","year":"2023","unstructured":"Hu Q, Chen Y, Deng X, Li Y, Ma X, Zeng J, et al. Diabetic nephropathy: Focusing on pathological signals, clinical treatment, and dietary regulation. Biomed Pharmacother. 2023;159:114252. https:\/\/doi.org\/10.1016\/j.biopha.2023.114252.","journal-title":"Biomed Pharmacother"},{"key":"3532_CR4","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.mpmed.2022.08.013","volume":"50","author":"PH Scanlon","year":"2022","unstructured":"Scanlon PH. Diabetic retinopathy. Medicine. 2022;50:696\u2013703. https:\/\/doi.org\/10.1016\/j.mpmed.2022.08.013.","journal-title":"Medicine"},{"key":"3532_CR5","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12933-022-01516-6","volume":"21","author":"CX Ma","year":"2022","unstructured":"Ma CX, Ma XN, Guan CH, Li YD, Mauricio D, Fu SB. Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management. Cardiovasc Diabetol. 2022;21:74 https:\/\/doi.org\/10.1186\/s12933-022-01516-6.","journal-title":"Cardiovasc Diabetol"},{"key":"3532_CR6","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41586-019-1797-8","volume":"576","author":"M Roden","year":"2019","unstructured":"Roden M, Shulman GI. The integrative biology of type 2 diabetes. Nature. 2019;576:51\u201360. https:\/\/doi.org\/10.1038\/s41586-019-1797-8.","journal-title":"Nature"},{"key":"3532_CR7","doi-asserted-by":"publisher","first-page":"6275","DOI":"10.3390\/ijms21176275","volume":"21","author":"U Galicia-Garcia","year":"2020","unstructured":"Galicia-Garcia U, Benito-Vicente A, Jebari S, Larrea-Sebal A, Siddiqi H, Uribe KB, et al. Pathophysiology of type 2 diabetes mellitus. Int J Mol Sci. 2020;21:6275 https:\/\/doi.org\/10.3390\/ijms21176275.","journal-title":"Int J Mol Sci"},{"key":"3532_CR8","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.mpmed.2018.10.009","volume":"47","author":"BT Srinivasan","year":"2019","unstructured":"Srinivasan BT, Davies M. Glycaemic management of type 2 diabetes. Medicine. 2019;47:32\u20139. https:\/\/doi.org\/10.1016\/j.mpmed.2018.10.009.","journal-title":"Medicine"},{"issue":"1","key":"3532_CR9","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1152\/physrev.00041.2018","volume":"100","author":"I Kimura","year":"2020","unstructured":"Kimura I, Ichimura A, Ohue-Kitano R, Igarashi M. Free fatty acid receptors in health and disease. Physiol Rev. 2020;100(1):171\u2013210. https:\/\/doi.org\/10.1152\/physrev.00041.2018.","journal-title":"Physiol Rev"},{"issue":"3","key":"3532_CR10","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1177\/10998004221142331","volume":"25","author":"TP Prado","year":"2023","unstructured":"Prado TP, Jara CP, Dias B\u00f3bbo VC, Carraro RS, Sidarta-Oliveira D, de Mendon\u00e7a GRA, et al. A free fatty acid synthetic agonist accelerates wound healing and improves scar quality in mice. Biol Res Nurs. 2023;25(3):353\u201366. https:\/\/doi.org\/10.1177\/10998004221142331.","journal-title":"Biol Res Nurs"},{"issue":"6928","key":"3532_CR11","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1038\/nature01478","volume":"422","author":"Y Itoh","year":"2003","unstructured":"Itoh Y, Kawamata Y, Harada M, Kobayashi M, Fujii R, Fukusumi S, et al. Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature. 2003;422(6928):173\u20136. https:\/\/doi.org\/10.1038\/nature01478.","journal-title":"Nature"},{"issue":"13","key":"3532_CR12","doi-asserted-by":"publisher","first-page":"11303","DOI":"10.1074\/jbc.M211495200","volume":"278","author":"CP Briscoe","year":"2003","unstructured":"Briscoe CP, Tadayyon M, Andrews JL, Benson WG, Chambers JK, Eilert MM, et al. The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids. J Biol Chem. 2003;278(13):11303\u201311. https:\/\/doi.org\/10.1074\/jbc.M211495200.","journal-title":"J Biol Chem"},{"issue":"4","key":"3532_CR13","doi-asserted-by":"publisher","first-page":"300","DOI":"10.2133\/dmpk.24.300","volume":"24","author":"GJ van der Vusse","year":"2009","unstructured":"van der Vusse GJ. Albumin as fatty acid transporter. Drug Metab Pharmacokinet. 2009;24(4):300\u20137. https:\/\/doi.org\/10.2133\/dmpk.24.300.","journal-title":"Drug Metab Pharmacokinet"},{"issue":"4","key":"3532_CR14","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1053\/j.gastro.2012.02.003","volume":"142","author":"K Cusi","year":"2012","unstructured":"Cusi K. Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: Pathophysiology and clinical implications. Gastroenterology. 2012;142(4):711\u201325.e6. https:\/\/doi.org\/10.1053\/j.gastro.2012.02.003.","journal-title":"Gastroenterology"},{"issue":"6","key":"3532_CR15","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1021\/ml1000855","volume":"1","author":"N Negoro","year":"2010","unstructured":"Negoro N, Sasaki S, Mikami S, Ito M, Suzuki M, Tsujihata Y, et al. Discovery of TAK-875: A potent, selective, and orally bioavailable GPR40 agonist. ACS Med Chem Lett. 2010;1(6):290\u20134. https:\/\/doi.org\/10.1021\/ml1000855.","journal-title":"ACS Med Chem Lett"},{"issue":"9","key":"3532_CR16","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1021\/ml300133f","volume":"3","author":"SP Brown","year":"2012","unstructured":"Brown SP, Dransfield PJ, Vimolratana M, Jiao X, Zhu L, Pattaropong V, et al. Discovery of AM-1638: A potent and orally bioavailable GPR40\/FFA1 full agonist. ACS Med Chem Lett. 2012;3(9):726\u201330. https:\/\/doi.org\/10.1021\/ml300133f.","journal-title":"ACS Med Chem Lett"},{"issue":"6","key":"3532_CR17","doi-asserted-by":"publisher","first-page":"e00278","DOI":"10.1002\/prp2.278","volume":"4","author":"Y Chen","year":"2016","unstructured":"Chen Y, Song M, Riley JP, Hu CC, Peng X, Scheuner D, et al. A selective GPR40 (FFAR1) agonist LY2881835 provides immediate and durable glucose control in rodent models of type 2 diabetes. Pharmacol Res Perspect. 2016;4(6):e00278 https:\/\/doi.org\/10.1002\/prp2.278.","journal-title":"Pharmacol Res Perspect"},{"issue":"2","key":"3532_CR18","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/j.bmcl.2011.10.118","volume":"22","author":"JB Houze","year":"2012","unstructured":"Houze JB, Zhu L, Sun Y, Akerman M, Qiu W, Zhang AJ, et al. AMG 837: A potent, orally bioavailable GPR40 agonist. Bioorg Med Chem Lett. 2012;22(2):1267\u201370. https:\/\/doi.org\/10.1016\/j.bmcl.2011.10.118.","journal-title":"Bioorg Med Chem Lett"},{"issue":"11","key":"3532_CR19","doi-asserted-by":"publisher","first-page":"404","DOI":"10.3390\/ph13110404","volume":"13","author":"S Kuranov","year":"2020","unstructured":"Kuranov S, Luzina O, Khvostov M, Baev D, Kuznetsova D, Zhukova N, et al. Bornyl derivatives of p-(Benzyloxy)Phenylpropionic acid: In vivo evaluation of antidiabetic activity. Pharmaceuticals (Basel). 2020;13(11):404 https:\/\/doi.org\/10.3390\/ph13110404.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"6","key":"3532_CR20","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.3390\/pharmaceutics15061670","volume":"15","author":"DA Pon\u2019kina","year":"2023","unstructured":"Pon\u2019kina DA, Kuranov SO, Marenina MK, Meshkova YV, Zhukova NA, Khvostov MV, et al. Bornyl-Containing derivatives of benzyloxyphenylpropanoic acid as FFAR1 agonists: In vitro and in vivo studies. Pharmaceutics. 2023;15(6):1670 https:\/\/doi.org\/10.3390\/pharmaceutics15061670.","journal-title":"Pharmaceutics"},{"key":"3532_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2021.127969","volume":"41","author":"P Governa","year":"2021","unstructured":"Governa P, Caroleo MC, Carullo G, Aiello F, Cione E, Manetti F. FFAR1\/GPR40: One target, different binding sites, many agonists, no drugs, but a continuous and unprofitable tug-of-war between ligand lipophilicity, activity, and toxicity. Bioorg Med Chem Lett. 2021;41:127969. https:\/\/doi.org\/10.1016\/j.bmcl.2021.127969.","journal-title":"Bioorg Med Chem Lett"},{"key":"3532_CR22","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1134\/S1068162020060151","volume":"46","author":"SO Kuranov","year":"2020","unstructured":"Kuranov SO, Luzina OA, Salakhutdinov NF. FFA1 (GPR40) receptor agonists based on phenylpropanoic acid as hypoglycemic agents: Structure\u2013Activity relationship. Russ J Bioorg Chem. 2020;46:972\u201388. https:\/\/doi.org\/10.1134\/S1068162020060151.","journal-title":"Russ J Bioorg Chem"},{"issue":"2","key":"3532_CR23","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1021\/acsmedchemlett.6b00443","volume":"8","author":"CW Plummer","year":"2017","unstructured":"Plummer CW, Clements MJ, Chen H, Rajagopalan M, Josien H, Hagmann WK, et al. Design and synthesis of novel, selective GPR40 AgoPAMs. ACS Med Chem Lett. 2017;8(2):221\u20136. https:\/\/doi.org\/10.1021\/acsmedchemlett.6b00443.","journal-title":"ACS Med Chem Lett"},{"issue":"9","key":"3532_CR24","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.2337\/db08-0307","volume":"57","author":"S Edfalk","year":"2008","unstructured":"Edfalk S, Steneberg P, Edlund H. Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion. Diabetes. 2008;57(9):2280\u20137. https:\/\/doi.org\/10.2337\/db08-0307.","journal-title":"Diabetes"},{"issue":"9","key":"3532_CR25","doi-asserted-by":"publisher","first-page":"8022","DOI":"10.3390\/ijms24098022","volume":"24","author":"SO Kuranov","year":"2023","unstructured":"Kuranov SO, Pon Kina DA, Meshkova YV, Marenina MK, Khvostov MV, Luzina OA, et al. Synthesis and evaluation of hypoglycemic activity of structural isomers of ((Benzyloxy)phenyl)propanoic acid bearing an aminobornyl moiety. Int J Mol Sci. 2023;24(9):8022 https:\/\/doi.org\/10.3390\/ijms24098022.","journal-title":"Int J Mol Sci"},{"key":"3532_CR26","doi-asserted-by":"publisher","first-page":"121","DOI":"10.15227\/orgsyn.081.0121","volume":"81","author":"WF Bailey","year":"2005","unstructured":"Bailey WF, Luderer MR, Mealy MJ, Punzalan ER. Generation and cyclization of 5-hexenyllithium: 2-cyclopentylacetophenone. OrgSyn. 2005;81:121\u201333. https:\/\/doi.org\/10.15227\/orgsyn.081.0121.","journal-title":"OrgSyn"},{"issue":"6","key":"3532_CR27","doi-asserted-by":"publisher","first-page":"e66744","DOI":"10.1371\/journal.pone.0066744","volume":"8","author":"P Sun","year":"2013","unstructured":"Sun P, Wang T, Zhou Y, Liu H, Jiang H, Zhu W, et al. DC260126: a small-molecule antagonist of GPR40 that protects against pancreatic \u03b2-Cells dysfunction in db\/db mice. PLoS ONE. 2013;8(6):e66744 https:\/\/doi.org\/10.1371\/journal.pone.0066744.","journal-title":"PLoS ONE"},{"issue":"11","key":"3532_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/ardp.70152","volume":"358","author":"MA Elkina","year":"2025","unstructured":"Elkina MA, Khvostov MV, Kuranov SO, Luzina OA, Zhukova NA, Meshkova YV, et al. Hypoglycemic and analgesic effects of benzyloxyphenylpropanoic derivatives of isobornylamine as FFAR-1 agonists. Arch Pharm (Weinheim). 2025;358(11):e70152. https:\/\/doi.org\/10.1002\/ardp.70152.","journal-title":"Arch Pharm (Weinheim)"},{"key":"3532_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.114668","volume":"164","author":"R Ma","year":"2023","unstructured":"Ma R, Lu D, Wang J, Xie Q, Guo J. Comparison of pharmacological activity and safety of different stereochemical configurations of borneol: L-borneol, D-borneol, and synthetic borneol. Biomed Pharmacother. 2023;164:114668. https:\/\/doi.org\/10.1016\/j.biopha.2023.114668.","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"3532_CR30","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1002\/jat.4388","volume":"43","author":"X Ni","year":"2023","unstructured":"Ni X, Yin X, Qi C, Liu C, Chen H, Zhou Y, et al. Cardiotoxicity of (\u2212)-borneol, (+)-borneol, and isoborneol in zebrafish embryos is associated with Na+\/K+-ATPase and Ca2+-ATPase inhibition. J Appl Toxicol. 2023;43(3):373\u201386. https:\/\/doi.org\/10.1002\/jat.4388.","journal-title":"J Appl Toxicol"},{"issue":"7","key":"3532_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2023.119511","volume":"1870","author":"M Palmgren","year":"2023","unstructured":"Palmgren M. Evolution of the sodium pump. Biochimica et biophysica acta. Mol Cell Res. 2023;1870(7):119511. https:\/\/doi.org\/10.1016\/j.bbamcr.2023.119511.","journal-title":"Mol Cell Res"},{"issue":"19","key":"3532_CR32","doi-asserted-by":"publisher","first-page":"8868","DOI":"10.1021\/acs.jmedchem.6b00685","volume":"59","author":"CM Azevedo","year":"2016","unstructured":"Azevedo CM, Watterson KR, Wargent ET, Hansen SV, Hudson BD, K\u0119pczy\u0144ska MA, et al. Non-Acidic free fatty acid receptor 4 agonists with antidiabetic activity. J Med Chem. 2016;59(19):8868\u201378. https:\/\/doi.org\/10.1021\/acs.jmedchem.6b00685.","journal-title":"J Med Chem"},{"issue":"13","key":"3532_CR33","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1080\/00397911.2010.551171","volume":"42","author":"SS Murphree","year":"2012","unstructured":"Murphree SS, Mason JD, Bean TG, Perry MC. Rapid aqueous borohydride reduction of carbonyls under sealed-tube microwave conditions. Synth Commun. 2012;42(13):1979\u201386. https:\/\/doi.org\/10.1080\/00397911.2010.551171.","journal-title":"Synth Commun"},{"issue":"4","key":"3532_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/M1899","volume":"2024","author":"B Lyu","year":"2024","unstructured":"Lyu B, Sako H, Sugiura M, Hiraga Y, Takagi R, Niwayama S. 1H NMR chemical shift changes as a result of introduction of Carbonyl-Containing protecting groups observed in bornol and isoborneol. Molbank. 2024;2024(4):M1899. https:\/\/doi.org\/10.3390\/M1899.","journal-title":"Molbank"},{"issue":"2","key":"3532_CR35","doi-asserted-by":"publisher","first-page":"152","DOI":"10.2337\/diacare.17.2.152","volume":"17","author":"MM Tai","year":"1994","unstructured":"Tai MM. A mathematical model for the determination of total area under glucose tolerance and other metabolic curves. Diabetes Care. 1994;17(2):152\u20134. https:\/\/doi.org\/10.2337\/diacare.17.2.152.","journal-title":"Diabetes Care"}],"container-title":["Medicinal Chemistry Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00044-026-03532-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00044-026-03532-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00044-026-03532-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T09:15:22Z","timestamp":1773393322000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00044-026-03532-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,25]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["3532"],"URL":"https:\/\/doi.org\/10.1007\/s00044-026-03532-7","relation":{},"ISSN":["1054-2523","1554-8120"],"issn-type":[{"value":"1054-2523","type":"print"},{"value":"1554-8120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,25]]},"assertion":[{"value":"26 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}